PTC THERAPEUTICS, INC. — Director's Dealing 2020

Nov 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2020-11-02

Reporting Person: Peltz Stuart Walter (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-02	Common Stock	M	50000	$10.85	Acquired	106085	Direct
2020-11-02	Common Stock	S	29073	$53.134	Disposed	77012	Direct
2020-11-02	Common Stock	S	9114	$53.863	Disposed	67898	Direct
2020-11-02	Common Stock	S	11813	$54.794	Disposed	56085	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-02	Stock Option (Right to Buy)	$10.85	M	50000	Disposed	2023-05-15	Common Stock (50000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right To Buy)	$490.8	2021-04-27	Common Stock (541.0)	541	Direct
Stock Option (Right To Buy)	$218.4	2022-01-10	Common Stock (416.0)	416	Direct
Stock Option (Right to Buy)	$10.85	2023-05-15	Common Stock (10694)	10694	Direct
Stock Option (Right To Buy)	$27.05	2024-01-27	Common Stock (200000.0)	200000	Direct
Stock Option (Right To Buy)	$51.0	2025-01-01	Common Stock (300000.0)	300000	Direct
Stock Option (Right To Buy)	$30.86	2026-01-03	Common Stock (175000.0)	175000	Direct
Stock Option (Right To Buy)	$11.23	2027-01-02	Common Stock (26000)	26000	Direct
Stock Option (Right To Buy)	$18.01	2028-01-02	Common Stock (200000.0)	200000	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (265000.0)	265000	Direct
Stock Option (Right To Buy)	$33.02	2029-01-21	Common Stock (55000.0)	55000	Direct
Stock Option (Right To Buy)	$51.16	2030-01-28	Common Stock (192500.0)	192500	Direct

Footnotes

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.42 to $53.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.42 to $54.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.42 to $55.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Currently exercisable.

F6: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

F7: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.

F8: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.

F9: This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.

F10: This option was granted on January 29, 2020 and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 29, 2021.